| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4001031 | Urologic Oncology: Seminars and Original Investigations | 2008 | 5 Pages |
Abstract
We have identified low and variable rates of tumor marker use in testis cancer cases recorded in SEER. As pay-for-performance evolves, standardized metrics for recommended processes of care (e.g., measurement of tumor markers in patients with testis cancer) may be tied to reimbursement. In this context, failure to document the use of tumor markers will be interpreted as less than optimal care.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Scott M. M.D., Stephanie M.S., Alon Z. M.D., John T. M.D., M.S., Brent K. M.D., M.S.,